Hospital Director Illegally Profited 27 Million, Exposed by Discipline Inspection Commission!
Fight against corruption in the current medical industry under the situation of the deepening, shocked the national hospital with illegal profits case came to light. Students in guangxi people's hospital of the former dean YangJianFeng, on suspicion of illegally in his accepting up to more than 2700 ten thousand yuan, have been dealt with harshly.
According to the official bulletin, YangJianFeng tenure from 2009 to 2023, using his dean position, intervention and manipulation of drug supplies, medical equipment, ambulances, procurement and construction of hospital infrastructure projects such as the key link, to take this opportunity, property illegally accept total achieved a staggering 2700 more than ten thousand yuan. In addition, he was involved in the serious problem of illegally charging patients.
After a thorough investigation, in April 2024, YangJianFeng was expelled from office and, the case has been transferred to the procuratorial organ to further review and prosecution. The disclosure of this case has once again brought the problem of corruption in the medical industry to the forefront. In recent years, the state has maintained a high-pressure situation in the anti-corruption work of the medical industry. So far, more than 30 hospital directors and secretaries have been publicly dealt with and notified for violating the law and discipline.
The regulatory level has also been adjusted accordingly, rising from the health system to the market supervision department, and further intensifying the anti-corruption efforts. At the same time, a nationwide large-scale hospital inspection work, in the ongoing has covered 16 provinces and regions. Everywhere in the process of inspection, pay special attention to medicine, medical supplies, information construction and so on easy to corruption, aims to fundamentally curb the occurrence of corruption.
Fight against corruption in the field of health care is a difficult and lasting task. Only by continuously strengthening regulatory measures and thoroughly cutting off the interest chain of corruption can we provide patients with more fair, transparent, clean and efficient medical services, which is the result of the common expectation of the whole society.
Looking for chemical products? Let suppliers reach out to you!
2026-07-11
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Alipay, Baidu, and iFlytek Win Big—As the Government Spends $1.1 Billion on AI Healthcare, Is This a Lifeline or a Feeding Frenzy for Tech Giants?
-
Sun Pharma’s Secret Sauce: Solve the Specific, Win the Market
-
The Oral GLP-1 Cage Match: Orforglipron vs Rybelsus
-
Sun Pharma’s Winning Formula: Precision Over Expansion
-
Merck to Lay Off 150 Workers at US Gardasil Plant Amid Sales Weakness
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff
-
AstraZeneca India Eyes ₹3,400 Crore Bengaluru Sale
-
Iran Conflict Leaves a Long Shadow on Drug Supply
-
Sun Pharma’s Organon Bid Would Redraw Indian Pharma M&A
Recommend Reading
-
BASF Raises API and Excipient Prices
-
U.S. Onshoring Debate Exposes API Raw-Material Gap
-
Pharmaceutical Tariffs Put Ingredients Back in Focus
-
IPEC Updates Excipient Qualification Guidance
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
72 Hours at API China: Where China’s API Export Industry Is Heading Next
-
ExxonMobil Shuts Another Singapore Facility: The Global Petrochemical Shake-Up Leaves No Easy Winners
-
U.S. Chemical Tariff Deadline Nears as the Industry Faces Cost Repricing and Supply-Chain Adjustment
-
Global Chemical Inventories Hit Critical Lows as Over 200 Chinese Companies Suspend Quotations
-
Formic Acid Market Supply Is Loose, Inventory Reduction Is Orderly